NCT01306474

Brief Summary

AIM: To study the expression of CD4+CD25+ high regulatory T cells in peripheral blood of patients with uveitis and to explore its role in the development of uveitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2009

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 1, 2011

Completed
Last Updated

March 3, 2011

Status Verified

March 1, 2011

Enrollment Period

1.1 years

First QC Date

February 28, 2011

Last Update Submit

March 2, 2011

Conditions

Uveitis

Keywords

CD4/CD25 Tr cell,TNF,IFN-γ,IL-2

Study Arms (2)

Prednisone

profess to convinced 1-1.5mg/Kg.d

methotrexate to band prednisone

profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Ages eligible for Study:18 Years to 60 Years. Study Population had two eye attacks in a year.

You may qualify if:

  • between 18 to 60 years
  • the first episode

You may not qualify if:

  • had other intracranial pathologies (e.g.tumor,infection)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology, Xijing Hosptial

Xi'an, Shaanxi, 710032, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Experimental:A Drug: prednisone profess to convinced 1-1.5mg/Kg.d Experimental:B Drug: methotrexate profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Study Officials

  • li cai, MD

    the ophthalmology department, xijing Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 28, 2011

First Posted

March 1, 2011

Study Start

July 1, 2009

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

March 3, 2011

Record last verified: 2011-03

Locations

CN(1)